제테마

216080KOSDAQ의료용품 및 기타 의약 관련제품 제조업

49.0 / 100

Reference Date: 2026-07-24

Financial Score14.0 / 40

News Sentiment21.0 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Slightly down 3.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Jetema develops and manufactures biopharmaceuticals based on hyaluronic acid fillers and botulinum toxin, as well as tissue sutures and lifting threads, expanding into both aesthetic and therapeutic markets. Key products like Jetema Dermal Toxin, which received domestic approval in 2024, are driving growth, with global expansion accelerated through licensing agreements with partners in Brazil, China, and Thailand.

Number of Employees

244people

Average Salary

4.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.184.0Point

PBR

2.52Industry Average 1.090.0Point

2.3x industry avg (risky)

ROE

-10.91Industry Average -4.893.5Point

2.2x industry avg (excellent)

Debt Ratio

92.88Industry Average 6.860.0Point

13.5x industry avg (risky)

Trend 2023~20256.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲14.5% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲24.5% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 2.1% (declining, 3yr)

Detailed News Sentiment

9 totalPositive 9Neutral 0Negative 0Average Sentiment Score 83.9

Positive
제테마, 브라질 안비자 GMP 실사 통과…중남미 시장 진출 가속화
제테마의 브라질 GMP 실사 통과로 중남미 시장 진출 가속화 기대.
Positive
제테마, '토탈 바이오 헬스케어' 비전 선포…"GLP-1·더마코스메틱 ...
제테마가 글로벌 바이오 헬스케어 기업으로의 비전을 선포하며 GLP-1 치료제와 더마 코스메틱 분야에서의 성장 전략을 발표해 긍정적인 시장 반응을 유도했다.
Positive
[단독] "필러·톡신 넘어 비만약 판매…종합 헬스케어 기업으로 전환.....
제테마 대표의 전략 발표로 비만약 상업화 및 종합 헬스케어 분야 진출 계획이 발표되어 긍정적인 시장 반응 예상.

Detailed Momentum

52-week position1.0Point

Near 52w low (3%, downtrend)

Current 4,390Won52-week high 10,89052-week low 4,185

1-month return2.0Point

1m -3.09% (slight drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

8 totalPositive 0Neutral 8Negative 0

Neutral[첨부정정]주요사항보고서(전환사채권발행결정)2026-07-07
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-03
Neutral주식등의대량보유상황보고서(일반)2026-07-03
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-02
Neutral투자판단관련주요경영사항 (제테마더톡신주 100단위(클로스트리디움 보툴리눔독소 A형)의 태국 (TFDA) 품목허가 획득)2026-07-02